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Background: The risks associated with gestational diabetes mellitus (GDM) are well recognized, and there is
increasing evidence to support treatment of the condition. However, clear guidance on the ideal approach to
screening for GDM is lacking. Professional groups continue to debate whether selective screening (based on risk
factors) or universal screening is the most appropriate approach. Additionally, there is ongoing debate about what
levels of glucose abnormalities during pregnancy respond best to treatment and which maternal and neonatal
outcomes benefit most from treatment. Furthermore, the implications of possible screening options on health care
costs are not well established. In response to this uncertainty there have been repeated calls for well-designed,
randomised trials to determine the efficacy of screening, diagnosis, and management plans for GDM. We describe a
randomised controlled trial to investigate screening uptake rates and the clinical and cost effectiveness of screening
in primary versus secondary care settings.
Methods/Design: This will be an unblinded, two-group, parallel randomised controlled trial (RCT). The target
population includes 784 women presenting for their first antenatal visit at 12 to 18 weeks gestation at two hospitals
in the west of Ireland: Galway University Hospital and Mayo General Hospital. Participants will be offered universal
screening for GDM at 24 to 28 weeks gestation in either primary care (n = 392) or secondary care (n = 392) locations.
The primary outcome variable is the uptake rate of screening. Secondary outcomes include indicators of clinical
effectiveness of screening at each screening site (primary and secondary) including gestational week at time of
screening, time to access antenatal diabetes services for women diagnosed with GDM, and pregnancy and neonatal
outcomes for women with GDM. In addition, parallel economic and qualitative evaluations will be conducted. The
trial will cover the period from the woman’s first hospital antenatal visit at 12 to 18 weeks gestation, until the
completion of the pregnancy.
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Gestational diabetes mellitus (GDM) has been defined by
the World Health Organization (WHO) as hyperglycaemia
of variable severity with onset or first recognition during
pregnancy [1]. The risks associated with gestational dia-
betes mellitus are well recognized. Pregnancies compli-
cated by GDM are associated with increased incidence
of both adverse maternal outcomes (pregnancy-induced
hypertension, polyhydramnios and caesarean section) and
neonatal outcomes (prematurity, large for gestational age,
neonatal unit admission, neonatal hypoglycaemia and re-
spiratory distress) [2,3]. Later in life, both the mother and
child are at increased risk of hospital admission, obesity,
type 2 diabetes and heart disease [2,4-7]. Fortunately, these
complications seem to be lessened by better detection and
management of the condition [8,9].
There is a lack of robust evidence relating to the preva-
lence of GDM internationally [10,11]. This is due in large
part to the use of a wide range of definitions and diagnos-
tic criteria [12-14], as well as variations in prevalence
across regions and ethnic groups [10,15].
Nonetheless, there is evidence that GDM affects signifi-
cant numbers of pregnancies each year and that the
prevalence of GDM has been increasing rapidly in recent
years [16]. In Ireland, a large-scale research study funded
by the Health Research Board and conducted by the
Atlantic Diabetes in Pregnancy (Atlantic DIP) consor-
tium, found that 12.4% of pregnancies in Ireland are
complicated by GDM [17] according to the IADPSG
(International Association of Diabetes and Pregnancy
Study Group) diagnostic criteria [12].
Despite the increasing prevalence of the disease and
the adverse consequences associated with it, there is still
significant uncertainty about the screening, diagnosis
and management of GDM [10,15].
In terms of screening, for example, professional groups
disagree on whether to recommend universal or selective
screening (based on risk factors) [12,18,19]. While some
studies have found that universal screening for GDM is
superior to risk factor-based screening in terms of num-
ber of cases detected, time to diagnosis and treatment,
and improved pregnancy outcomes [20,21], others have
found no such effects. For example, a review of four tri-
als comparing universal and selective screening, found
that there is little high-quality evidence on the effects of
screening for GDM on health outcomes for mothers and
their babies. The paper concluded that further research
is required to see which recommendations for screening
practices for GDM are most appropriate [22].
Additionally, the site of screening is likely to be im-
portant, both in terms of the location of the screen (re-
gional versus local) and in terms of the provider of the
screening service (GP versus hospital). For example The
Atlantic DIP study, which offered universal screening toall pregnant women, recorded an uptake rate of only
44% [17]. Follow-up analysis to explain this low screen-
ing uptake rate revealed that travel distance to the hos-
pital screening site is an important factor in determining
uptake rates [23]. Specifically, the probability of attend-
ing for screening is 15% lower for a patient who lives 50
kilometers from a screening centre, compared to an
otherwise similar patient who lives closer to the hospital.
The corresponding reduction in the probability of at-
tending for an individual residing 100 kilometers away is
30%. This suggests that the availability of GDM screen-
ing in local (primary care) settings could result in higher
uptake rates; however, this has not been empirically
tested to date.
It is possible that service provider differences may im-
pact on uptake rates too. Given that the oral glucose toler-
ance test (OGTT) screen involves three blood draws and
takes in excess of two hours to complete, it is conceivable
that factors such as wait time, space and comfort in the
waiting area, and perceived skill of the phlebotomist/
nurse/GP, may influence the decision to attend. However,
to date, no evidence exists on this issue. Additionally, evi-
dence is needed in order to determine if the site of GDM
screening will impact health outcomes; It is possible that
there may be differences between primary and secondary
care in terms of timeliness of screening, access to results,
communication of results to patients, or access to GDM
treatment for those with positive test results.
There is also a lack of consensus surrounding which
pregnancy outcomes can be influenced by GDM man-
agement. Earlier published work found little evidence for
an effect of treatment on various perinatal outcomes
[24,25]. A 2003 Cochrane Collaboration systematic re-
view also concluded that ‘there are insufficient data for
any reliable conclusions about the effects of treatments
for impaired glucose tolerance on perinatal outcomes’
[26]. However, more recent evidence has shown a bene-
ficial effect of treatment. For example, in a RCT compar-
ing GDM treatment versus routine care for mildly
diabetic patients (that is, those not having overt dia-
betes), Crowther [8] found that treatment for GDM re-
duced the rate of serious perinatal outcomes (death,
shoulder dystocia, bone fracture, and nerve palsy) from
4% to 1%. Rates of caesarean section delivery were simi-
lar in the two groups. On the other hand, another study
[27] showed no significant difference in a combined end-
point analysis between treated and untreated women, al-
though treatment did lower the risks of fetal overgrowth,
shoulder dystocia, caesarean delivery and pre-eclampsia.
Recent meta-analyses have shown treatment effects for
some perinatal complications - for example, shoulder
dystocia, large for gestational age (LGA) and macroso-
mia in the infant, and pre-eclampsia in the mother
[28-30]. Thus, while the evidence is mounting for the
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outcomes can be influenced and, moreover, what degree
of carbohydrate intolerance will benefit most from treat-
ment [28,31]. In response to this uncertainty there have
been repeated calls for well-designed, randomised trials to
determine the efficacy of screening, diagnosis, and man-
agement of GDM.
Screening in Ireland
In Ireland, although guidelines exist, there is no nation-
ally implemented screening policy for GDM. However,
the Atlantic DIP networka [1] advocates a universal
screening approach for all pregnant women [17]. Part of
the rationale for this policy is that research has shown
that implementation of selective screening would de-
crease the number of screens by only 10% while adding
significantly to the complexity of the screening process
[32]. Currently in Ireland, GDM screening is only of-
fered at secondary care sites. Limiting screening to hos-
pital sites can result in geographical inequalities in
access to screening. Additionally, since screening for
GDM facilitates the identification of women who are at
risk of developing type 2 diabetes in the future and who
should undergo long-term health surveillance and pre-
ventative measures, women residing in more remote lo-
cations are more disadvantaged in terms of both their
short- and long-term health.
Thus, it is important to understand if offering a screen-
ing programme in primary care would improve uptake
rates, access to treatment and pregnancy outcomes. Find-
ing answers to these questions could have important im-
plications for the planning and provision of future GDM
screening services nationally. The challenge to the health
service is to provide a screening programme that accur-
ately identifies the population at risk and is able to ensure
that the uptake rate in the population at risk is on par
with international norms for screening programmes. In
order to do this, evidence is required on the clinical and
cost effectiveness of alternative screening models that
could be introduced. A primary versus secondary care
based universal screening programme for GDM has not
been previously explored or evaluated.
In this paper, we detail an RCT to compare the relative
clinical and cost effectiveness of a primary versus second-
ary care based universal screening programme for GDM.
The primary outcome variable is screening uptake rate at
each site. Secondary outcomes include gestational age at
time of screen, timing of access to antenatal diabetes care
services for women with GDM, and pregnancy outcomes
for women with GDM. In parallel, we will investigate the
cost implications of primary versus secondary care
screening. We will also conduct a qualitative analysis of
user and stakeholder attitudes, preferences, barriers and
facilitators of screening at each site.Objectives
The aim of the trial is to assess the uptake, clinical and
cost effectiveness of universal screening for GDM in pri-
mary care versus secondary care locations.
Hypothesis
The formal null hypothesis to be tested in this study is
that there is no difference in uptake of screening for
GDM amongst women randomised to primary care
screening compared to women randomised to secondary
care screening.
Methods/Design
Unblinded, parallel group, randomised controlled trial
A randomised controlled trial will be conducted to com-
pare the uptake, clinical effectiveness and cost effective-
ness of universal screening for GDM in primary versus
secondary care. The CONSORT guidelines [33] for the
conduct of RCTs will be employed in the design and
analysis of the trial. The trial is registered with the Inter-
national Standard Randomised Controlled Trial Number,
ISRCTN02232125.
Interventions
All women who consent to participate in the study will
be invited for a 2-hour, 75 g, oral glucose tolerance test
(OGTT) at between 24 to 28 weeks gestation. Partici-
pants will be randomised into either the primary care
screening group or the secondary care screening group.
The scheduling process differs slightly between groups.
In the primary care group, the GP is requested to sched-
ule the OGTT screening appointment with the woman;
in the secondary care group researchers schedule the
screening appointment during the recruitment phone
calls. In neither group is the responsibility for scheduling
the appointment left to the woman.
Primary care screening group: All women randomised
to the primary care screening group will be offered a
screening appointment for GDM at their local general
practitioner (GP) clinic. Following randomisation, a study
information leaflet and the materials required to perform
an OGTT will be sent to the woman’s GP by the research
team. The GP is requested to contact the woman in order
to schedule the OGTTappointment at 24 to 28 weeks ges-
tation. As per usual care, the GP will send the test samples
to the local laboratory for analysis. Following analysis, the
laboratory will send the test results directly to the GP and
the GP will inform the woman of her result. For positive
test results, the GP will be directed to contact the local
maternity unit to make an appointment for the woman to
be seen at the diabetes antenatal service.
Secondary care screening group: All women rando-
mised to the secondary care screening group will be
offered a screening appointment at the hospital site.
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schedule the appointment for the OGTT screen and
send the list of OGTT appointments to the maternity
unit, for inclusion in their OGTT appointment diary. As
per usual care, the test samples will be sent to the local
laboratory for analysis. Following analysis, the laboratory
will send the test results directly to the consulting ob-
stetrician, who in turn informs the woman of her result.
For positive test results, an appointment will be made by
the midwife for the woman to attend the antenatal dia-
betes service.
Setting
This study will run concurrently at two sites: Galway
University Hospital (GUH) and Mayo General Hospital
(MGH) and their associated network of general practi-
tioner (GP) clinics and primary care teams. GUH is the
lead Atlantic DIP network site with approximately 4,000
deliveries per year. GUH serves both urban and rural
populations, including Galway city, the third largest city
in Ireland. MGH serves a rural population and has ap-
proximately 2,300 deliveries per year. Thus, GUH and
MGH patients can be considered as broadly representa-
tive of the general population of Ireland. Within this
geographical region is a network of general practitioners
(Western Research and Educational Network: WestREN)
who are interested in pursuing research in the commu-
nity in collaboration with colleagues in secondary care.
WestREN includes more than 80 general practices and
more than 400,000 patients along the western seaboard
of Ireland. Recently published research confirms that the
WestREN practices and patients are representative of
Ireland generally [34].
In advance of the commencement of the trial, all GPs
in the Galway and Mayo region will be sent a trial infor-
mation leaflet and asked to formally opt-out if they do
not wish to participate. Additionally, GPs will be
instructed to inform the study team if they are unable to
perform the OGTT test, in such circumstances the par-
ticipant will be offered a screen in secondary care.
Participants
The recruitment population is pregnant women present-
ing for their first antenatal visit at GUH and MGH at 12
to 18 weeks gestation. Participation in the study ends on
completion of the pregnancy. All expectant mothers in
Ireland are entitled to the Maternity and Infant Care
Scheme, which consists of a shared programme of care
provided by GPs in primary care and obstetricians in the
hospital maternity units, or secondary care. The care
scheme provides for an initial examination with the GP
before 12 weeks gestation, followed by a hospital ap-
pointment and scan at 12 to 18 weeks gestation,
followed by 6 further examinations alternated betweenthe GP clinic and the maternity unit over the course of
the pregnancy. Screening for GDM is embedded in hos-
pital practice and supported by protocols.
Eligibility criteria
 Inclusion criteria: Women presenting with a
pregnancy at GUH and MGH during the
recruitment phase will be included.
 Exclusion criteria: Women with established diabetes
or diagnosed GDM will be excluded.
Recruitment
Recruitment for the trial will be initiated at the woman’s
first hospital visit at 12 to 18 weeks gestation. A list of
all women with a confirmed pregnancy presenting at the
obstetrics outpatient clinics at GUH and MGH will be
obtained from the hospital databases by the principal in-
vestigator, who is a member of the clinical care team at
both sites. Each woman will be sent an invitation letter,
participant information leaflet and participant consent
form in the post. The information will be followed up
with a phone call to each woman to answer questions
and obtain verbal consent before randomising those who
consent to the primary care and secondary care screen-
ing groups. The baseline characteristic questionnaire will
be administered at this time. The phone calls will be
conducted by members of the research team. Each con-
senting woman will be asked to return the written con-
sent form to the study office. For some of the
participants (that is, those who meet the risk factor cri-
teria for selective GDM screening), an appointment for
an OGTT may have already been scheduled at their 12
to 18 week hospital visit. In such cases, researchers will
continue the randomisation process as usual and inform
the clinic if a change is required to the screening sched-
ule. Those who were not selected for screening at the 12
to 18 week clinic but who consent to the study and are
randomised into the secondary care screening group will
be added to the hospital’s screening schedule. Outcome
data will not be collected from participants who discon-
tinue. The flow chart in Figure 1 represents the move-
ment of a participant through the stages of recruitment.
Sample size and power calculation
On the basis of a comparison of two proportions a sam-
ple of 784 is needed to have 80% power, at the 5% sig-
nificance level, to detect a ≥10% change in screening
uptake. To achieve the required sample size, 1,513 pa-
tients will be invited to participate in the RCT, as 74%
recruitment and 30% patient attrition (seen in Atlantic
DIP) is anticipated. Recruitment will continue until tar-
get sample size is reached.
Figure 1 Participant flow through recruitment process.
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The randomisation process in this RCT will use random
permuted blocks to ensure similar numbers of partici-
pants in each intervention arm throughout the trial and
equal numbers in each arm by the end of the study.
Blocks of varying length will be used to reduce the pre-
dictability of the allocation sequence. In advance of par-
ticipant recruitment, an independent researcher will be
responsible for generating the allocation sequence using
the NQuery statistical software program (version 2.0).
(Statistical Solutions, Cork, Ireland; www.statistical-solu
tions-software.com) Sealed envelopes will be used to
assign participants to intervention groups. Thus, the
allocation sequence will be concealed from all study
researchers until the interventions are assigned.
Laboratory analysis
All test samples will be analysed at the local hospital la-
boratory. For those women presenting at GUH, analysis
will take place at the GUH laboratory; for those women
presenting at MGH, analysis will take place at the MGH
Laboratory. Each test sample will have a study-specificlabel to enable identification. Laboratory samples for
plasma glucose were analysed using the hexokinase
method (Roche Modular P Analytics Chemistry Systems).
GDM will be defined according to the new International
Association of Diabetes and Pregnancy Study Groups
(IADPSG) criteria [35]. We will apply the cut-off values
for a diagnosis of GDM as follows: fasting, 1 hour or 2
hour glucose values of ≥5.1 mmol/l (92 mg/dl), 10 mmol/l
(180 mg/dl) or 8.5 mmol/l (153 mg/dl), respectively.
GDM diagnosis and treatment, antenatal, delivery and
neonatal care
All women with positive test results will be offered
GDM treatment. This will involve lifestyle intervention,
blood glucose self-monitoring and, if required, insulin.
In terms of lifestyle intervention, all women will be of-
fered consultations with a dietician and a diabetes nurse
specialist. In terms of blood glucose self-monitoring, all
women will be educated and instructed to self-monitor
over the remainder of their pregnancy. Women who do
not respond to lifestyle intervention after two weeks will
be prescribed insulin for the remainder of the pregnancy.
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vided by specialists in diabetes and obstetrics in second-
ary care and by the woman’s GP. All deliveries will take
place at the local hospital.
Data collection
Data collection has two components: baseline character-
istic data and clinical outcome data. These are described
below.
Baseline characteristic data
In order to compare participants in both screening arms,
clinical risk factor data and socioeconomic status data
will be collected during the recruitment phase, using the
baseline characteristic questionnaire (Table 1).
Clinical outcome data
Data on a range of clinical outcomes will be collected to
explore the clinical effectiveness of the alternative
screening programmes. Two sources of data are used:
 Hospital and laboratory database reviews:
Data will be extracted from the hospital and
laboratory databases on test results, processes
of care and pregnancy outcomes.
 Chart searches: Antenatal care documents
(combined care cards) will be reviewed at the
end of the study to capture processes of care for
GDM women, over the course of the pregnancy.Table 1 Baseline characteristic data




Personal and family history of diabetes
Smoking status
Hypertension
Previous pregnancy ending in perinatal death
Current medications








Distance and journey time from hospital and GP
settings
Mode of transportOutcomes
Primary outcome: uptake of screening
The primary outcome in the RCT is uptake of screening
in the primary care and secondary care settings. First,
the number of screening offers accepted will be assessed
by comparing the number of screens offered (via the ob-
stetrics outpatient clinic list) with the number of offers
accepted (via the randomisation schedule). Second the
uptake rate will be determined by comparing the num-
ber of women randomised to each setting to the number
of OGTTs performed in that setting (via the GUH and
MGH laboratory records).
Secondary outcome 1: GDM prevalence
The prevalence of GDM in primary and secondary care
settings is a secondary outcome in the RCT. Analysis of
the laboratory database will enable the identification of
GDM prevalence in both screening groups.
Secondary outcome 2: timing of screening
The timing of screening in primary and secondary care
settings is a secondary outcome in the RCT. Analysis of
the laboratory database will enable a determination of
gestational age at the time of screening in both screening
groups.
Secondary outcome 3: time to access antenatal diabetes
care for women with GDM
The time to access GDM treatment for positive GDM
cases in the primary and secondary care settings is a
secondary outcome in the RCT. The Diabetes Clinical
Management System (DIAMOND) will be used to collect
data on the date of first access to specialist diabetes ante-
natal care for women diagnosed with GDM. This will en-
able analysis of time of access to care in both screening
groups.
Secondary outcome 4: pregnancy outcomes for women
with GDM
Pregnancy outcomes for positive GDM cases in the pri-
mary and secondary care settings are a secondary out-
come in the RCT. The DIAMOND Diabetes Clinical
Management System will be used for the collection of
data on a range of maternal and neonatal outcomes for
women diagnosed with GDM (Table 2).
Analysis plan
Differences in patient characteristics in primary care ver-
sus secondary care will be presented using suitable numer-
ical and graphical summaries. A nonlinear mixed model
for a binomial response will be used to compare the pro-
portion of uptake between those in primary and secondary
care while adjusting for differences in patient characteris-
tics at baseline as appropriate. The analysis of the secondary




Outcome variable Assessment method
Primary Uptake of screening laboratory database
Secondary 1 GDM prevalence laboratory database
Secondary 2 Timing of screening laboratory database
Secondary 3 Time to access antenatal
diabetes care
Hospital database










Foetal death intrauterine (FDIU)
Stillbirth
Admission to neonatal
intensive care unit (NICU)
Length of stay at NICU
Gestational age








respiratory distress, need for
phototherapy, birth trauma,
5-minute Apgar score less
than 7, or prematurity).
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for continuous and categorical responses and survival
models for the analysis of time to event data. The main
analysis will follow an intention-to-treat strategy; sensitiv-
ity analyses and per protocol analysis will be used to ex-
plore the effect of departures from the assumption made
in the main analysis. All analyses will be performed using
R Statistical advice and analysis will be provided by Dr.
John Newell of the HRB Clinical Research Facility, NUI
Galway.Study management
A study management group will be formed comprising
the principal investigator, co-investigators and trial stat-
istician. A data monitoring committee is not required as
the study management group will liaise every month to
review interim analysis and monitor adherence. The
principal investigator will make the final decision to ter-
minate the trial in the event that uptake rates fall below
pre-trial levels in either intervention arm. It is not antici-
pated that there will be premature termination of study.
However, if this occurs, then the data will be analysed
and results circulated to team members. The ethics
committee will be notified of premature termination and
the reasons for termination. Adverse events or other un-
intended effects of trial interventions that come to the
attention of trial investigators will be reported immedi-
ately to the study management Group. All protocol
amendments will be submitted to the ethics committee
for review and approval before implementation and to
trial registries.
Data protection and participant confidentiality
Data acquired according to this protocol will be re-
corded on a password-protected database on a secure
network. All entries will be made by an authorised mem-
ber of the investigator’s staff. Data will be entered into
the study database and verified through the use of pro-
grammed edit checks for accuracy and completeness.
The corrected data and a complete audit trail of correc-
tions will be retained. An internal audit of a sample of
the data will be conducted quarterly to assure quality.
The investigator will insure that participants’ anonym-
ity is maintained. Participants will not be identified by
their names, but by their assigned identification number
and initials. The investigator will keep a separate log of
subjects’ identification numbers, names, addresses, tele-
phone numbers and hospital numbers. Signed informed
consent forms, will be maintained securely. Only autho-
rized members of the investigator’s staff will have access
to the final trial dataset.
All information regarding the study data or results
supplied to the investigator is privileged and confidential
information. The investigator agrees to use this informa-
tion to accomplish the study and will not use it for other
purposes.
Economic evaluation
The economic evaluation will incorporate both cost-
effectiveness analysis and cost-utility analysis for the
alternative screening options. The basic tasks of the
evaluation are to identify, measure, value and compare
the costs and outcomes of the alternative screening loca-
tions. A societal-costing perspective will be adopted as
costs are likely to fall on patients, their families and the
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costs of organising and operating the two programmes.
These costs will reflect the time input of health profes-
sionals and fixed or overhead costs. All contacts with
the health services will be recorded and valued. The pa-
tient and family costs include any out-of-pocket ex-
penses and any own time input into the screening
process, including time foregone as part of any treat-
ment process. To complete the analysis, cost data will be
combined with effectiveness data on the primary out-
come from the trial; that is, uptake of screening. In
addition, Quality Adjusted Life-Years (QALYs) will be
estimated in order to enable comparisons with interven-
tions from within and beyond maternity care. To this
end, modeling techniques to compute QALYs will be
employed. The analysis will use standard economic ana-
lysis for the calculation of costs and incremental cost-
effectiveness ratios. Unit costs will be applied to the
resource use data to calculate the various costs of care.
Comparisons between the two screening groups will be
made on the outcomes above and costs will be assigned
accordingly. Analyses will report the incremental cost ef-
fectiveness from a societal perspective and from a pub-
licly funded health system perspective in line with
Health Information Quality Assessment (HIQA) guid-
ance [36]. Budget-impact analyses for the primary and
secondary care based screening strategies will be under-
taken. Uni- and multivariate sensitivity analyses, as well
as a probabilistic sensitivity analysis, will be used to
address uncertainty in the study.Qualitative analysis
Pre-trial phase
In order to maximize user involvement in the design of
the screening process, pre-trial interviews and focus
groups will be held with users and stakeholders includ-
ing women with previous experience of GDM screening,
primary care teams both urban and rural, and secondary
care teams.Post-trial phase
In order to explore the psychological impact of GDM
screening and diagnosis on maternal experience and
well-being, post-trial interviews and focus groups will be
held with women from both the primary care and sec-
ondary care screening groups, and women who tested
positive and negative for GDM at each site. Attitudes to
and perceptions of GDM screening in primary and sec-
ondary care, including barriers and facilitators of screen-
ing at each site, will also be explored. In addition, the
attitudes and experiences of stakeholders will be ex-
plored through interviews and focus groups with stake-
holders involved in the trial. Stakeholder groups willinclude GP practice staff, hospital obstetric outpatient
staff, and laboratory staff.
The findings of the qualitative analysis, along with the
findings from the trial itself, will inform the recommen-
dations for a national GDM screening programme.
Trial status
Enrolment into the study will begin in January 2013. Re-
cruitment is expected to be complete by December
2014.
Ethical approval for this research was obtained from
the Clinical Research Ethics Committee, Galway Univer-
sity Hospitals, Health Service Executive of Ireland, 5
December 2012 (Ref: C.A.753).
Endnotes
aThe Atlantic DIP Network was established in 2005 to
provide robust information on pregnancy outcomes for
women with diabetes across five regional hospital cen-
tres along the Irish Atlantic seaboard.
bMedical Card status refers to a card issued by the
Health Service Executive which entitles the holder of the
card to a range of Health Services free of charge.
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